Profile data is unavailable for this security.
About the company
EssilorLuxottica SA, formerly known as Essilor International Compagnie Generale D Optique SA, is a France-based ophthalmic company. The Company designs, manufactures and markets a range of lenses, frames and sunglasses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories and instruments, and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, which includes corrective lenses, optical instruments intended for opticians and optometrists; Equipment, which includes machines and consumables used by plants and prescription laboratories, and Sunglasses & Readers, which encompasses non-prescription reading glasses and non-prescription sunglasses. The Company operates under a number of brands, including Ray-Ban, Oakley and Varilux, among others. The Company operates in Europe, North America, Asia Pacific, the Middle East, Africa and Latin America.
- Revenue in EUR (TTM)15.01bn
- Net income in EUR1.23bn
- Incorporated1993
- Employees150.62k
- LocationEssilorLuxottica SA147 rue de ParisCHARENTON-LE-PONT 94220FranceFRA
- Phone+33 149774224
- Fax+33 149774420
- Websitehttps://www.essilor-luxottica.com
Mergers & acquisitions
| Acquired company | EL:PAR since announced | Transaction value |
|---|---|---|
| GrandVision NV | 17.55% | 6.20bn |
| Brille24 GmbH | 30.64% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sonova Holding AG | 2.70bn | 578.40m | 14.58bn | 14.99k | 25.32 | 6.89 | 19.77 | 5.41 | 9.57 | 9.57 | 44.58 | 35.19 | 0.66 | 3.14 | 6.75 | 195,806.30 | 14.30 | 11.32 | 18.49 | 14.01 | 71.25 | 69.25 | 21.66 | 16.27 | 0.7224 | 73.05 | 0.2298 | 41.08 | 4.43 | 7.21 | 13.49 | 5.91 | 4.49 | 8.83 |
| Straumann Holding AG | 1.37bn | 269.85m | 14.93bn | 6.68k | 55.34 | 12.82 | 44.03 | 10.94 | 18.20 | 18.20 | 92.08 | 78.56 | 0.742 | 1.88 | 4.41 | 245,572.00 | 14.79 | 15.83 | 18.46 | 18.33 | 75.33 | 76.72 | 19.93 | 20.79 | 1.04 | 14.60 | 0.2834 | 34.12 | 22.61 | 14.93 | -2.42 | 21.93 | 54.05 | 6.96 |
| Sartorius Stedim Biotech SA | 1.34bn | 237.95m | 15.03bn | 5.95k | 62.97 | 13.68 | 49.14 | 11.26 | 2.59 | 2.59 | 14.54 | 11.92 | 0.8352 | 2.58 | 5.63 | 236,961.50 | 14.97 | 12.47 | 20.33 | 16.59 | 51.59 | 50.89 | 17.93 | 14.71 | 0.7766 | 24.45 | 0.1337 | 25.85 | 12.13 | 15.55 | 29.15 | 25.71 | 43.24 | 23.30 |
| Smith & Nephew plc | 4.47bn | 631.01m | 20.03bn | 16.00k | 31.77 | 4.47 | 19.22 | 4.48 | 0.6076 | 0.6076 | 4.31 | 4.31 | 0.5942 | 0.8967 | 3.98 | 230,312.70 | 8.38 | 8.62 | 10.02 | 10.47 | 73.87 | 74.21 | 14.10 | 13.38 | 0.9613 | 15.19 | 0.3056 | 45.33 | 2.92 | 2.42 | -17.02 | 3.58 | 0.4084 | 5.19 |
| Coloplast A/S | 2.40bn | 518.28m | 22.72bn | 12.07k | 47.17 | 26.35 | 37.53 | 9.46 | 18.18 | 18.18 | 84.19 | 32.54 | 1.46 | 3.16 | 5.95 | 1,485,755.00 | 31.62 | 27.20 | 52.16 | 47.22 | 67.75 | 67.96 | 21.59 | 19.82 | 0.8956 | 49.55 | 0.1488 | 100.87 | 9.06 | 7.62 | 0.7282 | 10.14 | 5.30 | 8.13 |
| Koninklijke Philips NV | 19.11bn | 1.36bn | 40.90bn | 79.61k | 31.24 | -- | 19.28 | 2.14 | 1.46 | 1.39 | 20.71 | -- | -- | -- | -- | 246,899.20 | -- | 2.44 | -- | 3.56 | 46.34 | 43.80 | 7.13 | 3.81 | -- | 18.74 | -- | 114.41 | 1.92 | -3.80 | 60.07 | 4.79 | -0.3289 | 1.22 |
| Siemens Healthineers AG | 14.52bn | 1.57bn | 45.10bn | 52.00k | 28.86 | 4.61 | 20.43 | 3.11 | 1.56 | 1.56 | 14.49 | 9.78 | 0.705 | 4.48 | 4.37 | 279,192.30 | 7.70 | -- | 10.49 | -- | 39.92 | -- | 10.92 | -- | 1.02 | 29.05 | 0.0143 | -- | 8.11 | -- | 23.87 | -- | -- | -- |
| EssilorLuxottica SA | 15.01bn | 1.23bn | 60.82bn | 150.62k | 43.13 | 1.80 | 22.62 | 4.05 | 3.22 | 3.22 | 42.55 | 77.25 | 0.495 | 3.53 | 6.76 | 99,630.85 | 4.45 | 6.61 | 5.43 | 8.71 | 61.15 | 60.75 | 9.00 | 12.35 | 0.7337 | 20.52 | 0.1557 | 40.85 | 17.58 | 16.35 | 4.52 | 12.88 | 19.04 | 16.76 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Dec 2019 | 9.95m | 2.28% |
| The Vanguard Group, Inc.as of 31 Dec 2019 | 8.52m | 1.95% |
| Norges Bank Investment Managementas of 31 Dec 2018 | 5.97m | 1.37% |
| Massachusetts Financial Services Co.as of 30 Nov 2019 | 4.45m | 1.02% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2019 | 4.23m | 0.97% |
| BlackRock Fund Advisorsas of 09 Jan 2020 | 4.22m | 0.96% |
| Amundi Asset Management SA (Investment Management)as of 31 Dec 2018 | 4.03m | 0.92% |
| WCM Investment Management LLCas of 16 Jan 2020 | 2.93m | 0.67% |
| Baillie Gifford & Co.as of 16 Jan 2020 | 2.92m | 0.67% |
| Comgest SAas of 30 Sep 2019 | 2.68m | 0.61% |
